SCHEMBL252539

SCHEMBL252539

O=C1CCc2ccc(OCCCCN3CCN(c4cccc5c4OCCO5)CC3)cc2N1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 20/20 1.00
DRD3 P35462 7/20 0.76
DRD4 P21917 6/20 0.76
DRD1 P21728 3/20 0.76
DRD5 P21918 3/20 0.76
HTR2A P28223 3/20 0.76
SLC6A4 P31645 2/20 0.70
HTR3E A5X5Y0 1/20 0.70
MEN1 O00255 1/20 0.70
MLNR O43193 1/20 0.70
HTR3B O95264 1/20 0.70
ABCB11 O95342 1/20 0.70
ESR1 P03372 1/20 0.70
PGR P06401 1/20 0.70
ADRB2 P07550 1/20 0.70
CHRM2 P08172 1/20 0.70
ABCB1 P08183 1/20 0.70
ADRB1 P08588 1/20 0.70
HTR1A P08908 1/20 0.70
ADRA2A P08913 1/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL252526 0.87 DRD2 (1.00) DRD2DRD3DRD4DRD1DRD5
SCHEMBL5374922 0.86 DRD2 (0.76) DRD2DRD3DRD4DRD1DRD5
SCHEMBL13532795 0.83 DRD2 (1.00) DRD2DRD3DRD4DRD1DRD5
Aripiprazole SCHEMBL29356997 0.82 DRD2 (1.00) DRD2DRD3DRD4DRD1DRD5
Aripiprazole SCHEMBL29475637 0.82 DRD2 (1.00) DRD2DRD3DRD4DRD1DRD5
Aripiprazole SCHEMBL29475638 0.82 DRD2 (1.00) DRD2DRD3DRD4DRD1DRD5
Aripiprazole SCHEMBL8255 0.82 DRD2 (1.00) DRD2DRD3DRD4DRD1DRD5
Aripiprazole SCHEMBL982189 0.82 DRD2 (1.00) DRD2DRD3DRD4DRD1DRD5
Aripiprazole SCHEMBL29438823 0.82 DRD2 (1.00) DRD2DRD3DRD4DRD1DRD5
SCHEMBL252864 0.82 DRD2 (1.00) DRD2DRD3DRD4DRD1DRD5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9156822-B2 Functionally selective ligands of dopamine D2 receptors THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 2015-10-13 US disclosed
US-9156822-B2 Functionally selective ligands of dopamine D2 receptors THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 2015-10-13 US disclosed
US-9156822-B2 Functionally selective ligands of dopamine D2 receptors THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 2015-10-13 US disclosed
US-20130137679-A1 Novel Functionally Selective Ligands of Dopamine D2 Receptors NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2013-05-30 US disclosed
US-20130137679-A1 Novel Functionally Selective Ligands of Dopamine D2 Receptors NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2013-05-30 US disclosed
US-20130137679-A1 Novel Functionally Selective Ligands of Dopamine D2 Receptors NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2013-05-30 US disclosed
WO-2012003418-A2 FUNCTIONALLY SELECTIVE LIGANDS OF DOPAMINE D2 RECEPTORS THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 2012-01-05 WO disclosed
WO-2012003418-A2 FUNCTIONALLY SELECTIVE LIGANDS OF DOPAMINE D2 RECEPTORS THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 2012-01-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130137679-A1 Novel Functionally Selective Ligands of Dopamine D2 Receptors DRD2, AVPR2, NTSR2 DRD2 1/4885DRD3 12/4885DRD4 41/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.